The Claim

Cut overdose deaths by 21% over last year, with overdose deaths declining each month since President Trump took office.

The Claim, Unpacked

What is literally being asserted?

Two factual claims: (1) drug overdose deaths fell by 21% compared to the prior year, and (2) overdose deaths declined in every single month since Trump’s inauguration on January 20, 2025.

What is being implied but not asserted?

That the Trump administration caused the 21% decline. That its policies — border enforcement, cartel sanctions, tariffs on fentanyl source countries — drove the reduction. That this represents a break from the prior trajectory rather than a continuation of it. That “cutting” overdose deaths is something a president does through policy action rather than something that happens through the convergence of public health, supply-side, and demographic factors. The placement in “MAKING OUR COMMUNITIES SAFE AGAIN” implies law enforcement and public safety interventions achieved this result.

What is conspicuously absent?

Any acknowledgment that overdose deaths were already declining for approximately 18 months before Trump took office. The CDC’s own data shows the downward trend began in mid-2023, with deaths falling 26.9% from 2023 to 2024 — entirely under the Biden administration. Any mention of the factors experts actually cite for the decline: naloxone availability (surging from 6,000 prescriptions in 2014 to 1.97 million in 2024), China’s precursor chemical crackdown (initiated through Biden-era diplomacy), the Sinaloa cartel civil war (which disrupted fentanyl production starting June 2024), declining fentanyl purity (from 19.2% to 10.3%), expanded treatment access through Medicaid and opioid settlement funds, and the Biden administration’s Overdose Data to Action (OD2A) investments. Any disclosure that the 12-month period ending January 2025 actually showed a slight uptick in deaths (approximately 1,400 more than the prior January period), contradicting “declining each month.” Any acknowledgment that the Trump administration has subsequently cut the very programs experts credit with driving the decline — $257+ million from SAMHSA addiction and overdose prevention programs, $588 million from NIH drug research, roughly $1 trillion from Medicaid including addiction care, and more than half of SAMHSA’s workforce.

Evidence Assessment

Established Facts

The 21% figure is approximately correct for a specific 12-month comparison, though the exact number depends on which period is measured. CDC provisional data shows the 12-month period ending August 2025 recorded approximately 73,000 overdose deaths, representing a 21% decline from the prior 12-month period (approximately 92,000 deaths). PolitiFact confirmed the 21.4% figure for the August 2024 to August 2025 comparison. The most recent CDC data (March 11, 2026 release) shows 71,542 predicted deaths for the 12-month period ending October 2025, a 17.1% decline — suggesting the year-over-year decline rate is itself decelerating as the baseline period increasingly reflects lower numbers. The 21% figure was accurate for the specific comparison window available around the January 20, 2026 publication date. [^055-a1]

The decline began approximately 18 months before Trump took office — this is a pre-existing trend, not a new one. CDC data shows the overdose death peak at 114,664 deaths in the 12-month period ending June 2023. Deaths fell consistently from mid-2023 onward: from 110,037 in calendar year 2023 to 80,391 in calendar year 2024 (26.9% decline). A June 2025 medical study confirmed that drug overdose deaths “sharply declined starting in mid-2023 during the Biden presidency.” By the time Trump was inaugurated on January 20, 2025, the decline had been underway for roughly 18 months and deaths had already fallen approximately 27% from the peak. The 21% decline claimed for the Trump period represents the continuation — and deceleration — of a trend inherited from the prior administration. [^055-a2]

The “declining each month” claim is not precisely supported by available data. The 12-month rolling count ending January 2025 — the very month Trump took office — showed approximately 82,138 deaths, with roughly 1,400 more deaths than the prior January period. NPR reported this as “the first time in more than a year” that the rolling count increased after 17 months of consecutive declines. Researcher Nabarun Dasgupta attributed the uptick to increases in Texas, Arizona, California, and Washington. Keith Humphreys (Stanford) warned it could be “an early warning that drug death declines could be fading.” While subsequent months resumed the downward trend, the claim that overdose deaths declined “each month” since inauguration is complicated by this January 2025 uptick at the very starting point. Additionally, five states — Arizona, Hawaii, Kansas, New Mexico, and North Dakota — experienced increases through most of 2025. [^055-a3]

Experts attribute the decline to multiple factors, none of which are primarily attributable to the Trump administration. The CDC’s February 2025 report attributed the decline to: (1) widespread naloxone distribution, (2) improved treatment access, (3) shifts in drug supply, (4) recovery from pandemic disruptions, and (5) CDC’s Overdose Data to Action (OD2A) investments. PolitiFact surveyed experts who cited: reduced fentanyl supply from China’s precursor crackdown (Biden-era diplomacy), smaller at-risk populations, naloxone surging to 1.97 million prescriptions, improved treatment access through medications like buprenorphine and methadone. Dr. Daniel Ciccarone attributed the decline to “a complex mix of supply and demand forces” and noted the “success of the Chinese regulation…is due to policies…during the Biden administration.” Regina LaBelle (Georgetown) called it “a complex societal problem requiring a multitude of solutions.” No expert has identified Trump administration policies as a primary driver. [^055-a4]

Strong Inferences

The Trump administration is actively cutting the programs experts credit with driving the decline. SAMHSA’s workforce was cut from approximately 900 to fewer than 450 employees (more than 50% reduction). At least $257 million in addiction and overdose prevention funding was cut, as part of a broader $1 billion SAMHSA reduction. The NIH lost $588 million in drug research grants. The CDC’s Injury Prevention Center (which focuses on overdose prevention) lost approximately 200 employees. In January 2026, up to 2,800 SAMHSA grants totaling $1.9 billion received termination letters before being largely restored after public backlash. Trump’s July 2025 executive order declared that SAMHSA grants would no longer “fund programs that fail to achieve adequate outcomes, including so-called ‘harm reduction’ or ‘safe consumption’ efforts.” SAMHSA removed its overdose prevention toolkit and harm reduction framework from its website. The administration proposed cutting roughly $1 trillion from Medicaid, including addiction treatment programs that Brookings researcher Richard Frank noted are responsible for treatment gains “largely due to the Medicaid expansion.” The contradiction is structural: the administration claims credit for declining overdose deaths while dismantling the programs that public health experts, the CDC itself, and peer-reviewed research identify as causes of that decline. [^055-a5]

The fentanyl cluster claims (Items #7, #46, #47, #48) and this overdose claim are counting the same underlying trend from different angles. Item #7 claims credit for reduced fentanyl trafficking. Item #46 claims credit for “forcing” Canada and Mexico to address fentanyl. Item #47 claims credit for tariffs on China targeting fentanyl precursors. Item #48 claims credit for “crippling” cartel sanctions. Item #55 claims credit for reduced overdose deaths. All five claims reference facets of the same complex phenomenon — declining fentanyl supply and declining overdose deaths — and attribute it to different Trump policies. But as established in Items #7, #46, #47, and #48, the decline is driven primarily by factors external to this administration: China’s precursor regulations (Biden-era), the Sinaloa cartel civil war, declining fentanyl purity, naloxone expansion, treatment access, and opioid settlement investments. Claiming credit five times for different aspects of the same inherited trend is a form of padding. [^055-a6]

Opioid settlement funds — negotiated and deployed before Trump — are contributing significantly to the decline. States and localities received over $6.5 billion in opioid settlement funds in 2024 and spent or committed $2.7 billion. Of committed funds, 23% ($615 million) went to treatment, 18% ($491 million) to harm reduction including $279 million for naloxone, and 17% ($450 million) to recovery services. These settlements, primarily negotiated and distributed under prior administrations, represent a massive infusion of resources into the treatment and prevention infrastructure that is helping drive the decline. The administration claims the outcome while having had no role in creating this funding pipeline. [^055-a7]

Informed Speculation

The claim’s placement in “MAKING OUR COMMUNITIES SAFE AGAIN” frames overdose death reduction as a law enforcement and public safety achievement. This framing is strategically important: it connects the administration’s preferred policy tools (border enforcement, cartel designations, tariffs) to a genuinely positive health outcome (fewer overdose deaths). But the causal chain runs primarily through public health infrastructure (naloxone, treatment, harm reduction) and external supply disruptions (China’s precursor regulations, cartel civil war) — not through law enforcement.

The administration faces a temporal problem that is becoming more visible. The 21% decline figure was measured for the 12-month period ending August 2025 — barely seven months into Trump’s presidency. The programs that experts credit (naloxone distribution networks, treatment access, OD2A investments, opioid settlement deployments) were built over years of Biden-era and bipartisan investment. These programs have long implementation timelines — it takes years to build treatment infrastructure, train providers, and establish naloxone distribution networks. Seven months is not enough time for any new administration’s policies to substantially alter overdose death rates, even if those policies were well-designed for this purpose. The administration’s actual policy contributions — border enforcement and cartel sanctions — address the supply side, which experts say explains only part of the decline. And even the supply-side improvements (China’s precursor regulations, cartel disruption) predate this administration.

The most concerning aspect is the forward-looking trajectory. The administration is cutting the programs that drove the decline while claiming credit for the decline. If SAMHSA’s $1 billion reduction, Medicaid cuts of roughly $1 trillion, NIH drug research cuts of $588 million, and the July 2025 executive order against harm reduction programs reduce treatment access, naloxone availability, and research capacity, the overdose death decline could slow, stall, or reverse — as the January 2025 uptick may have foreshadowed. Regina LaBelle warned: “The biggest risk really of increasing overdose deaths is the Medicaid cutbacks.” The administration may be spending down the public health capital accumulated by its predecessors.

Structural Analysis

The attribution problem (the foundational issue). This is the same attribution problem analyzed in Items #7, #46, #47, and #48 — but applied to the outcome rather than the inputs. A complex phenomenon driven by multiple independent causes is attributed entirely to one administration that inherited the trend already in progress. The decline began in mid-2023. It accelerated in 2024. It continued into 2025. The contributing factors — naloxone expansion, treatment access, China’s precursor controls, cartel disruption, declining purity, opioid settlement funds, OD2A investments — were all in place before January 20, 2025. The claim says “cut overdose deaths” as if the administration wielded the scissors. The evidence shows the cuts were being made by many hands, most of them predating this administration.

The padding lens. When combined with Items #7 (fentanyl seizure decline), #46 (Canada/Mexico fentanyl steps), #47 (China fentanyl tariffs), and #48 (cartel sanctions), this claim represents the fifth time the administration takes credit for different aspects of the same underlying phenomenon. The fentanyl supply decline and overdose death decline are facets of the same complex trend. Claiming each facet as a separate “win” inflates the list while the total number of independently verifiable policy achievements does not change.

Stated vs. revealed preferences. The stated preference is reducing overdose deaths. The revealed preference is reducing them through law enforcement and border security rather than public health. The administration’s actual policy actions — cutting SAMHSA by $1 billion, proposing $1 trillion in Medicaid cuts, defunding harm reduction, firing half the addiction and mental health agency’s staff — contradict the stated goal of reducing overdose deaths. If reducing overdose deaths were the genuine priority, the administration would be expanding the programs the CDC credits with driving the decline, not dismantling them.

Cui bono. The overdose crisis, like fentanyl, is a bipartisan concern with deep public sympathy. By claiming credit for declining deaths, the administration connects its broader “tough on crime” and “secure the border” narrative to a universally valued outcome. This framing justifies border enforcement, cartel designations, and tariffs by linking them to saved lives — even when the actual causal chain runs through public health programs the administration is cutting.

Follow the money. The $56 billion in opioid settlement funds flowing to states and localities represents the largest investment in addiction treatment and prevention in American history. This money was negotiated through years of litigation against pharmaceutical companies, distributed under bipartisan frameworks, and is being deployed by state and local governments regardless of federal policy. It is a significant driver of the decline that operates entirely independently of White House policy. The administration claims the output while the inputs come from the judicial system, state governments, and the Obama and Biden administrations’ health investments.

Context the Framing Omits

The decline started 18 months before inauguration. CDC data shows the peak at 114,664 deaths (12-month ending June 2023). By January 2025, deaths had fallen approximately 27% from this peak. The 21% further decline in 2025 is the continuation — and deceleration — of an inherited trend.

The CDC attributes the decline to public health programs, not law enforcement. The CDC’s own February 2025 report credits naloxone distribution, treatment access, supply shifts, and its Overdose Data to Action (OD2A) program. These are public health interventions, not border enforcement.

The January 2025 uptick contradicts “declining each month.” The 12-month period ending January 2025 showed approximately 1,400 more deaths than the prior January period — the first increase after 17 consecutive months of decline. While subsequent months resumed declining, the claim of continuous monthly decline is not precisely supported.

The administration is cutting the programs that drove the decline. SAMHSA lost more than half its staff, $1 billion+ in funding, and its harm reduction programs. NIH lost $588 million in drug research grants. CDC’s overdose prevention center lost 200 employees. The July 2025 executive order attacked harm reduction programs. Medicaid faces roughly $1 trillion in proposed cuts, threatening the addiction treatment access that experts credit for declining deaths.

No expert identifies Trump policies as a primary driver. Dr. Daniel Ciccarone, Regina LaBelle, Peter Reuter, Keith Humphreys, the CDC, and PolitiFact’s expert survey all attribute the decline to multiple factors — naloxone, treatment, supply disruption, demographic shifts — none of which are primarily the result of this administration’s policies.

This is the same trend counted for the fifth time. Items #7, #46, #47, #48, and #55 all claim credit for different aspects of the same underlying fentanyl supply decline and overdose death reduction. The 365-item list treats one complex phenomenon as five separate wins.

Opioid settlement funds are a major driver the administration had no role in creating. Over $6.5 billion in opioid settlement funds reached states in 2024, with billions deployed for treatment, naloxone, and recovery services. These settlements were negotiated under prior administrations.

Verdict

Factual core: The 21% figure is approximately correct for the 12-month period ending August 2025 compared to the prior year. Overdose deaths did decline substantially during 2025, with the most recent data (October 2025 ending period) showing 71,542 predicted deaths — returning to pre-pandemic levels. This is a genuinely positive development. The decline is real, and the lives saved are real.

The claim is mostly true but fundamentally misattributed:

1. The trend predates this administration by 18 months. Overdose deaths peaked in mid-2023 and fell 26.9% in 2024 — entirely under Biden. The 2025 decline is the continuation of an inherited trajectory, not a new one. The rate of decline is actually decelerating (from 27% in 2024 to 21% in the period ending August 2025 to 17% in the period ending October 2025).

2. “Declining each month” is not precisely true. The 12-month period ending January 2025 showed an uptick of approximately 1,400 deaths compared to the prior January period, and five states experienced increases through 2025. The overall trend is downward, but the claim of continuous monthly decline overstates the regularity of the data.

3. Experts credit public health programs, not this administration. The CDC, peer-reviewed research, and surveyed experts attribute the decline to naloxone expansion, treatment access, China’s precursor regulations (Biden-era diplomacy), cartel disruption, declining fentanyl purity, and opioid settlement investments — not to border enforcement, tariffs, or cartel sanctions.

4. The administration is actively undermining the programs that drove the decline. SAMHSA’s $1 billion reduction, proposed Medicaid cuts of roughly $1 trillion, NIH drug research cuts, harm reduction program defunding, and the loss of half the federal addiction agency’s workforce threaten to slow or reverse the progress the administration claims as a win.

Framing as “win”: Mostly true but misattributed. The 21% decline is a real statistic measuring a genuinely positive outcome. But “cut overdose deaths” implies causation that the evidence does not support. The administration inherited a declining trend driven by public health investments, supply-side disruptions, and naloxone expansion — all of which predate January 20, 2025. It is now cutting the programs experts identify as responsible for that decline. The most accurate framing would be: “Overdose deaths continued a decline that began in mid-2023, falling approximately 21% in the 12-month period ending August 2025. This decline is driven by expanded naloxone availability, improved treatment access, China’s precursor chemical regulations (initiated under the Biden administration), the Sinaloa cartel civil war, declining fentanyl purity, and billions in opioid settlement investments. The current administration’s contribution is uncertain; its subsequent cuts to SAMHSA, Medicaid, and harm reduction programs threaten to reverse this progress.”

What a reader should understand: The 21% decline in overdose deaths is real and represents tens of thousands of lives saved — that is genuinely good news. But the decline began in mid-2023, approximately 18 months before Trump took office, and the 2024 decline of 27% (under Biden) was actually larger than the 2025 decline of 21% (under Trump). The causes are well-documented: naloxone went from 6,000 prescriptions in 2014 to nearly 2 million in 2024; China cracked down on fentanyl precursor chemicals following Biden-era diplomatic engagement; the Sinaloa cartel civil war disrupted fentanyl production; fentanyl purity plummeted; treatment access expanded through Medicaid and opioid settlements. No expert attributes this decline primarily to Trump administration policies. Most concerning, the administration is now cutting the very programs experts credit: SAMHSA lost more than half its staff and over $1 billion in funding, harm reduction programs were defunded by executive order, Medicaid faces roughly $1 trillion in cuts, and NIH drug research lost $588 million. The claim takes credit for a pre-existing trend while undermining the foundations on which that trend stands. This is the fifth item in the fentanyl cluster (along with Items #7, #46, #47, and #48) to claim credit for different facets of the same underlying phenomenon.

Cross-References

• Item #7: “Cut fentanyl trafficking at the southern border by 56%” — the companion supply-side claim. Item #7 establishes the multi-causal drivers of fentanyl decline (China’s precursor regulations, Sinaloa cartel civil war, declining purity, naloxone) that predate this administration. Item #55’s overdose death decline is the downstream outcome of the same factors. Together, these items claim credit for both the supply reduction and the mortality outcome as separate “wins.”
• Item #46: “Forced Canada and Mexico to take meaningful steps to address fentanyl” — shares the attribution problem. Mexico’s enforcement escalation began under Sheinbaum in October 2024; Canada’s response targeted a negligible threat. The overdose decline is independent of both countries’ enforcement actions.
• Item #47: “Implemented an additional 10% tariff on imports from China in order to stem the flow of illegal aliens and fentanyl” — experts across the political spectrum agree tariffs are ineffective against fentanyl. China’s precursor regulations, which experts actually credit, were the product of Biden-era diplomacy.
• Item #48: “Imposed crippling sanctions on some of the world’s most deadly cartels” — the DEA’s own 2025 assessment shows cartels remain operational despite sanctions. The Sinaloa cartel’s disruption came from internal civil war, not financial sanctions.

Sources

CDC NCHS. “Provisional Drug Overdose Death Counts.” NVSS Vital Statistics Rapid Release. March 11, 2026. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

CDC NCHS. “U.S. Overdose Deaths Decrease Almost 27% in 2024.” May 14, 2025. https://www.cdc.gov/nchs/pressroom/releases/20250514.html

CDC. “CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths.” February 25, 2025. https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html

STAT News. “U.S. Overdose Deaths Fell Through Most of 2025, CDC Data Says.” January 14, 2026. https://www.statnews.com/2026/01/14/us-overdose-deaths-fell-through-most-of-2025/

PolitiFact. “What’s Driving Down US Overdose Deaths? Experts Cite Drug Supply Changes, Increased Naloxone.” January 29, 2026. https://www.politifact.com/article/2026/jan/29/drug-overdose-deaths-decline-naloxone-treatment/

NPR. “New Report: U.S. drug overdose deaths rise again after hopeful decline.” June 18, 2025. https://www.npr.org/2025/06/18/nx-s1-5436711/overdose-drugs-cdc

NPR. “As drug deaths hit a 5-year low, Trump continues to cite fentanyl as major threat.” August 30, 2025. https://www.npr.org/2025/08/30/nx-s1-5522046/drugs-deaths-trump-fentanyl

NPR. “In one year, Trump pivots fentanyl response from public health to drug war.” December 31, 2025. https://www.npr.org/2025/12/31/nx-s1-5653370/trump-fentanyl-drug-policy-pivot

FactCheck.org. “Trump Again Overstates Number of Drug Overdose Deaths in U.S.” September 5, 2025. https://www.factcheck.org/2025/09/trump-again-overstates-number-of-drug-overdose-deaths-in-u-s/

STAT News. “Trump cuts have decimated the federal addiction and mental health agency.” October 30, 2025. https://www.statnews.com/2025/10/30/samhsa-grant-cuts-staff-reductions-impact-analyzed/

Drug Policy Alliance. “Federal Cuts to Overdose Prevention & Addiction Treatment.” September 2, 2025. https://drugpolicy.org/resource/federal-cuts-threaten-overdose-prevention/

DEA. “DEA Releases 2025 National Drug Threat Assessment.” May 15, 2025. https://www.dea.gov/press-releases/2025/05/15/dea-releases-2025-national-drug-threat-assessment

KFF Health News. “Payback: Tracking the Opioid Settlement Cash.” 2025. https://kffhealthnews.org/opioid-settlements/

Johns Hopkins Opioid Principles. “2024 National Settlement Fund Tracking Project: What We Learned.” 2025. https://opioidprinciples.jhsph.edu/2024-national-settlement-fund-tracking-project-what-we-learned/

Fox News. “Drug overdose deaths declined 20% in 2025 amid increased border crackdown.” 2026. https://www.foxnews.com/us/us-drug-overdose-deaths-plummet-20-trump-administration-cracks-down-southern-border